Vaso occlusive crisis is the most common clinical manifestation of sickle cell disease. It is responsible for a significant volume of hospitalizations and emergency department visits by the affected patients. Recent studies suggest that nearly half of the people suffering from sickle cell disease experience vaso occlusive crisis, with some patients having 6 or more such episodes every year. Repeated episodes can lead to severe health complications and thus, there is a heightened impetus to develop effective drugs to alleviate the condition.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing vaso occlusive crisis pipeline development activities.
For the acute management of vaso occlusive crisis, opioids are commonly given to the patient for pain relief. Hydroxyurea, an antimetabolite chemotherapeutic agent, is also widely used to prevent painful crises in sickle cell anemia patients. In recent years, Adakveo (crizanlizumab) and Endari (L-glutamine) were cleared by the US Food and Drug Administration (FDA) as vaso occlusive crisis-preventing therapies. Further, in December 2023, a major milestone was achieved with the FDA approval of the first-ever cell-based gene therapy based on CRISPR/Cas9, Casgevy, for the treatment of sickle cell disease patients aged 12 years and above with recurrent vaso-occlusive crises. The rise in the development and regulatory approval of novel gene therapies are among the major trends, impacting the drug pipeline outlook positively.
Key Questions Answered in the Vaso Occlusive Crisis - Pipeline Insight Report
This product will be delivered within 3-5 business days.
Report Coverage
The Vaso Occlusive Crisis Drug Pipeline Report by the publisher gives comprehensive insights into vaso occlusive crisis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vaso occlusive crisis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The vaso occlusive crisis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from vaso occlusive crisis.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing vaso occlusive crisis pipeline development activities.
Vaso Occlusive Crisis Drug Pipeline Outlook
A vaso occlusive crisis, or VOC, refers to a condition when sickled red blood cells block the flow of blood to the extent that the tissues experience oxygen deprivation. This triggers an inflammatory response that leads to substantial pain which primarily occurs in the chest, back, or extremities. Besides causing acute pain, a vaso occlusive event can make the patient prone to various health issues such as strokes, arthritis, and kidney failure.For the acute management of vaso occlusive crisis, opioids are commonly given to the patient for pain relief. Hydroxyurea, an antimetabolite chemotherapeutic agent, is also widely used to prevent painful crises in sickle cell anemia patients. In recent years, Adakveo (crizanlizumab) and Endari (L-glutamine) were cleared by the US Food and Drug Administration (FDA) as vaso occlusive crisis-preventing therapies. Further, in December 2023, a major milestone was achieved with the FDA approval of the first-ever cell-based gene therapy based on CRISPR/Cas9, Casgevy, for the treatment of sickle cell disease patients aged 12 years and above with recurrent vaso-occlusive crises. The rise in the development and regulatory approval of novel gene therapies are among the major trends, impacting the drug pipeline outlook positively.
Vaso Occlusive Crisis - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of vaso occlusive crisis drug candidates based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The vaso occlusive crisis therapeutic assessment report covers 50+ drug analyses based on drug classes:
- Corticosteroids
- Immunosuppressive Agents
- Intravenous Immunoglobulins (IVIG)
- Cytotoxic Agents
- Monoclonal Antibodies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Vaso Occlusive Crisis - Pipeline Assessment Segmentation, By Phases
The vaso occlusive crisis report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for vaso occlusive crisis. There are around 31 drugs in phase II for vaso occlusive crisis.Vaso Occlusive Crisis - Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under vaso occlusive crisis pipeline analysis include analgesics, anti-sickling agents, monoclonal antibodies, amino acid supplements, and gene therapy. These drugs are prescribed according to the symptoms and the underlying cause of vaso occlusive crisis.Vaso Occlusive Crisis Clinical Trials Therapeutic Assessment - Competitive Dynamics
The vaso occlusive crisis drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in vaso occlusive crisis clinical trials:- AstraZeneca
- Novartis Pharmaceuticals
- Hoffmann-La Roche
- Pfizer
- Asklepion Pharmaceuticals, LLC
- Mast Therapeutics, Inc.
- GlycoMimetics Incorporated
- Anthera Pharmaceuticals
- Reprixys Pharmaceutical Corporation
- Beam Therapeutics Inc.
Vaso Occlusive Crisis - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for vaso occlusive crisis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of vaso occlusive crisis drug candidates.Crovalimab
Sponsored by Hoffmann-La Roche, the drug is being investigated as an adjunct treatment to help prevent vaso-occlusive episodes (VOE) in sickle cell disease. The study is being conducted at 41 locations including the United States and Brazil.Inclacumab
The Phase 3 study, involving vaso occlusive crisis drug candidate inclacumab (a P-selectin inhibitor), is sponsored by Pfizer. The safety and efficacy of the drug in reducing the frequency of vaso-occlusive crises will be assessed in 240 participants with sickle cell disease.Sufentanil
Sufentanil is an opioid analgesic that is currently in Phase III clinical development. The INVOPE trial will evaluate intranasal sufentanil in pediatric patients with sickle cell disease experiencing severe vaso-occlusive pain crisis.Crizanlizumab
Crizanlizumab, a monoclonal antibody medication, is used to reduce the frequency of vaso-occlusive crises. Novartis Pharmaceuticals is conducting a study to examine the safety and establish dosing of the drug in pediatric sickle cell disease patients.Reasons To Buy This Report
The Vaso Occlusive Crisis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for vaso occlusive crisis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into vaso occlusive crisis collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.Key Questions Answered in the Vaso Occlusive Crisis - Pipeline Insight Report
- Which companies/institutions are leading the vaso occlusive crisis drug development?
- What is the efficacy and safety profile of vaso occlusive crisis pipeline drugs?
- Which company is leading the vaso occlusive crisis pipeline development activities?
- What is the current vaso occlusive crisis commercial assessment?
- What are the opportunities and challenges present in the vaso occlusive crisis drug pipeline landscape?
- What is the efficacy and safety profile of vaso occlusive crisis pipeline drugs?
- Which company is conducting major trials for vaso occlusive crisis drugs?
- Which companies/institutions are involved in vaso occlusive crisis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in vaso occlusive crisis?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Vaso Occlusive Crisis
4 Patient Profile: Vaso Occlusive Crisis
5 Vaso Occlusive Crisis: Epidemiology Snapshot
6 Vaso Occlusive Crisis: Market Dynamics
7 Vaso Occlusive Crisis: Key Facts Covered
8 Vaso Occlusive Crisis, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Vaso Occlusive Crisis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Vaso Occlusive Crisis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Vaso Occlusive Crisis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Vaso Occlusive Crisis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Vaso Occlusive Crisis, Key Drug Pipeline Companies
